Literature DB >> 10634821

The private hepatocyte nuclear factor-1alpha G319S variant is associated with plasma lipoprotein variation in Canadian Oji-Cree.

R A Hegele1, H Cao, S B Harris, A J Hanley, B Zinman, P W Connelly.   

Abstract

We previously showed an extremely strong association between type 2 diabetes and a private polymorphism, namely G319S, in the hepatocyte nuclear transcription factor (HNF)-1alpha. Because HNF-1alpha is involved in the transcription of several apolipoprotein genes, we tested for an association between the private HNF1A G319S variant and plasma lipoproteins in a sample of 55 unrelated Oji-Cree subjects with type 2 diabetes and 175 unrelated Oji-Cree subjects without type 2 diabetes. In Oji-Cree subjects with type 2 diabetes, we found that the HNF1A G319S genotype was significantly associated with lower plasma concentrations of total cholesterol, low density lipoprotein cholesterol, and apolipoprotein (apo) B. In Oji-Cree subjects without type 2 diabetes, we found that the HNF1A G319S genotype was significantly associated with higher plasma concentrations of high density lipoprotein cholesterol and apo AI. There were no associations with plasma triglycerides or lipoprotein(a). Regression analysis indicated that the HNF1A genotype accounted for approximately 10% of the variation in the apo B-related traits in the diabetic subjects and for approximately 5% of the variation in the apo AI-related traits in the nondiabetic subjects. Furthermore, the regression model indicated that the HNF1A S319 allele affected these traits in a dominant manner in subjects with and without type 2 diabetes. These findings provide the first evidence that a rare variant in a nuclear transcription factor is associated with variation in plasma lipoprotein traits.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10634821     DOI: 10.1161/01.atv.20.1.217

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  9 in total

Review 1.  Monogenic dyslipidemias: window on determinants of plasma lipoprotein metabolism.

Authors:  R A Hegele
Journal:  Am J Hum Genet       Date:  2001-10-26       Impact factor: 11.025

2.  Genetically defined elevated homocysteine levels do not result in widespread changes of DNA methylation in leukocytes.

Authors:  Pooja R Mandaviya; Roby Joehanes; Dylan Aïssi; Brigitte Kühnel; Riccardo E Marioni; Vinh Truong; Lisette Stolk; Marian Beekman; Marc Jan Bonder; Lude Franke; Christian Gieger; Tianxiao Huan; M Arfan Ikram; Sonja Kunze; Liming Liang; Jan Lindemans; Chunyu Liu; Allan F McRae; Michael M Mendelson; Martina Müller-Nurasyid; Annette Peters; P Eline Slagboom; John M Starr; David-Alexandre Trégouët; André G Uitterlinden; Marleen M J van Greevenbroek; Diana van Heemst; Maarten van Iterson; Philip S Wells; Chen Yao; Ian J Deary; France Gagnon; Bastiaan T Heijmans; Daniel Levy; Pierre-Emmanuel Morange; Melanie Waldenberger; Sandra G Heil; Joyce B J van Meurs
Journal:  PLoS One       Date:  2017-10-30       Impact factor: 3.240

3.  HNF1α defect influences post-prandial lipid regulation.

Authors:  Matthieu St-Jean; François Boudreau; André C Carpentier; Marie-France Hivert
Journal:  PLoS One       Date:  2017-05-11       Impact factor: 3.240

Review 4.  HNF1A:From Monogenic Diabetes to Type 2 Diabetes and Gestational Diabetes Mellitus.

Authors:  Li-Mei Li; Bei-Ge Jiang; Liang-Liang Sun
Journal:  Front Endocrinol (Lausanne)       Date:  2022-03-01       Impact factor: 5.555

Review 5.  Transcriptional control by HNF-1: Emerging evidence showing its role in lipid metabolism and lipid metabolism disorders.

Authors:  Fang Liu; Xiao Zhu; Xiaping Jiang; Shan Li; Yuncheng Lv
Journal:  Genes Dis       Date:  2021-07-19

6.  HNF1A gene polymorphisms and cardiovascular risk factors in individuals with late-onset autosomal dominant diabetes: a cross-sectional study.

Authors:  Fernando M A Giuffrida; Gilberto K Furuzawa; Teresa S Kasamatsu; Marcos M Oliveira; Andre F Reis; Sergio A Dib
Journal:  Cardiovasc Diabetol       Date:  2009-06-02       Impact factor: 9.951

7.  Preliminary analysis of immune activation in early onset type 2 diabetes.

Authors:  Julia D Rempel; Juliet Packiasamy; Heather J Dean; Jonathon McGavock; Alyssa Janke; Mark Collister; Brandy Wicklow; Elizabeth A C Sellers
Journal:  Int J Circumpolar Health       Date:  2013-08-05       Impact factor: 1.228

8.  A new susceptibility locus for myocardial infarction, hypertension, type 2 diabetes mellitus, and dyslipidemia on chromosome 12q24.

Authors:  Salma M Wakil; Nzioka P Muiya; Asma I Tahir; Mohammed Al-Najai; Batoul Baz; Editha Andres; Nejat Mazhar; Nada Al Tassan; Maie Alshahid; Brian F Meyer; Nduna Dzimiri
Journal:  Dis Markers       Date:  2014-06-26       Impact factor: 3.434

9.  Common variants at 30 loci contribute to polygenic dyslipidemia.

Authors:  Sekar Kathiresan; Cristen J Willer; Gina M Peloso; Serkalem Demissie; Kiran Musunuru; Eric E Schadt; Lee Kaplan; Derrick Bennett; Yun Li; Toshiko Tanaka; Benjamin F Voight; Lori L Bonnycastle; Anne U Jackson; Gabriel Crawford; Aarti Surti; Candace Guiducci; Noel P Burtt; Sarah Parish; Robert Clarke; Diana Zelenika; Kari A Kubalanza; Mario A Morken; Laura J Scott; Heather M Stringham; Pilar Galan; Amy J Swift; Johanna Kuusisto; Richard N Bergman; Jouko Sundvall; Markku Laakso; Luigi Ferrucci; Paul Scheet; Serena Sanna; Manuela Uda; Qiong Yang; Kathryn L Lunetta; Josée Dupuis; Paul I W de Bakker; Christopher J O'Donnell; John C Chambers; Jaspal S Kooner; Serge Hercberg; Pierre Meneton; Edward G Lakatta; Angelo Scuteri; David Schlessinger; Jaakko Tuomilehto; Francis S Collins; Leif Groop; David Altshuler; Rory Collins; G Mark Lathrop; Olle Melander; Veikko Salomaa; Leena Peltonen; Marju Orho-Melander; Jose M Ordovas; Michael Boehnke; Gonçalo R Abecasis; Karen L Mohlke; L Adrienne Cupples
Journal:  Nat Genet       Date:  2008-12-07       Impact factor: 38.330

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.